Background-In high-cardiovascular-risk treated hypertensive patients, the incidence of cardiovascular events has been reported to relate to visit-to-visit blood pressure (BP) variability. We investigated whether visit-to-visit BP variability is prognostically important in treated mildly to moderately hypertensive patients in whom treatment aims at avoiding events but also at preventing or delaying progression of organ damage. Methods and Results-We analyzed the pooled data from the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind 4-year trial of the effect of lacidipine or atenolol on echographic carotid intima-media thickness. Visit-to-visit BP variability was assessed by the coefficient of variation or the SD of the mean on-treatment systolic BP (SBP) obtained at 6-(clinic BP) and 12-(24 hours BP) month intervals, respectively (1521 and 1264 patients, respectively). In a multivariable linear regression model, mean on-treatment clinic or 24-hour SBP, but not SBP coefficient of variation or SD, was associated with end-of-treatment carotid intima-media thickness. Intima-media thickness increased progressively from the lowest to highest quartile of mean on-treatment clinic or 24-hour SBP (adjusted P for trendϭ0.046 and 0.048) but not along similar quartiles of SBP coefficient of variation or SD. In a multivariable logistic regression model, mean BP, but not variability, was associated with cardiovascular outcomes. Conclusions-In mildly to moderately hypertensive patients, carotid intima-media thickness and cardiovascular outcomes were related to the mean clinic or ambulatory SBP achieved by treatment but not to on-treatment visit-to-visit clinic or 24-hour BP variability. Thus, when BP is modestly elevated, inconsistency of BP control between visits plays a less important prognostic role than long-term average BP levels. (Circulation. 2012;126:569-578.)
P ost hoc analyses of morbidity/mortality trials have recently reported that in treated hypertensive patients, the incidence of cardiovascular events increases progressively with the increase in the SD or coefficient of variation (CV) of the mean individual blood pressure (BP) value achieved during the treatment period (visit-to-visit intraindividual variability). 1, 2 This suggests that the protective effect of antihypertensive treatment depends not only on the magnitude of the achieved mean BP reduction but also on how consistent this reduction is, ie, how stable the on-treatment BP control is over the long term. However, direct analysis of the predictive role of long-term intraindividual BP variability has so far been limited to 2 trials of antihypertensive treatment, the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) and the Medical Research Council Trial of Treatment of Hypertension in Older Adults (MRC-elderly), 2 whereas a metaanalysis extended to a larger number of trials has used interindividual BP variability. 3 This represents the range of the effect of BP treatment in the patient group that has a different biological meaning and can at best be considered a surrogate of visit-to-visit intraindividual BP variability. 1, 4, 5 
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Furthermore, morbidity/mortality trials of antihypertensive treatment address mainly patients at high cardiovascular risk because of the need to obtain a sufficiently large number of events over the relatively few years of the duration of a trial to achieve enough statistical power. For example, in the 2 trials in which the role of intraindividual BP variability has been investigated (ASCOT, MRC-elderly), the incidence of major cardiovascular events (myocardial infarction, stroke, cardiovascular death) was 18.4 and 25.2 per 1000 patientyears, respectively. 6, 7 This means that no information exists on the role of visit-to-visit BP variability in mildly to moderately hypertensive patients in whom the primary goal is not only to prevent events but also to protect against progression to a higher-risk condition by the onset or worsening of subclinical organ damage. 8, 9 Providing this information was the aim of the present analysis of the European Lacidipine Study on Atherosclerosis (ELSA) trial in which randomized antihypertensive treatment based on either a calcium antagonist or a ␤-blocker was administered for 4 years to mildly or moderately hypertensive patients at relatively low cardiovascular risk (incidence of major cardiovascular events, 8.4 per 1000 patient-years). 10 Because the primary end point of the trial was treatment-induced changes in carotid intima-media thickness (IMT), we could investigate the role of visit-to-visit BP variability on a subclinical organ damage of documented prognostic significance. 11, 12 Because in ELSA patients BP was repeatedly measured not only in the clinic but also over 24 hours, information could be obtained on the role of visit-to-visit ambulatory BP variability. Information on mortality and morbidity was also available in ELSA, and the relation of visit-to-visit BP variability to these outcomes has also been investigated.
Methods

Study Design and Patients
The design and methods of the ELSA trial have been described elsewhere. 10 Briefly, ELSA was a prospective, multicenter, randomized, double-blind trial comparing the effect of long-term lacidipine or atenolol treatment on the progression of carotid artery IMT in mild to moderate essential hypertension. Randomization criteria were age between 45 and 75 years, sitting diastolic BP (DBP) between 95 and 115 mm Hg, fasting serum cholesterol concentration Յ320 mg/dL, serum triglyceride concentration Յ300 mg/dL, serum creatinine Յ1.7 mg/dL, a readable ultrasound carotid artery scan with an IMT of Յ4.0 mm, no recent myocardial infarction, and no insulindependent diabetes mellitus.
The included patients were washed from any previous treatment over a period of 4 weeks, after which they were randomized to the administration of atenolol 50 mg or lacidipine 4 mg, both administered on a once-a-day basis. If after 1 month clinic BP was not Ͻ95 mm Hg, the daily dose of either drug was increased (to 100 mg atenolol and 6 mg lacidipine), with the addition of open-label hydrochlorothiazide (12.5 and 25.0 mg daily) if the clinic DBP value was still uncontrolled after 2 additional months. Patients and trial personnel were blinded to treatment assignment for the 4 years of the trial duration.
Clinic BP Measurements
Clinic BP was measured by a mercury sphygmomanometer at randomization (baseline), at monthly intervals during the titration period, and at 6 months thereafter. Measurements were made according to a strict protocol by trained physicians from the hypertension centers participating in the trial. The first and fifth phases of Korotkoff sounds were taken to indicate systolic BP (SBP) and DBP values, respectively. At each visit, 3 measurements were obtained with the patient in the sitting position for at least 5 minutes and reported on the clinical research forms. The average of the 3 SBP and DBP values was used as the representative value for each visit.
Ambulatory BP Measurements
Ambulatory BP was measured after the washout period (baseline) and yearly thereafter. Only monitoring devices validated according to international protocols were used. 13 The monitoring began in the morning after the inflation cuff had been wrapped around the nondominant arm and the automatic readings had been programmed every 15 minutes during the day (6 AM to midnight) and every 20 minutes during the night (midnight to 6 AM). Patients were instructed to undergo their usual activity during the monitoring period, to keep the arm extended and immobile during the automatic cuff inflations, and to return the following day for device removal. The recordings were analyzed centrally and edited from artifacts according to prespecified criteria, which were those recommended by international guidelines to obtain accurate individual ambulatory BP recordings. 14 Only ambulatory BP monitorings in which valid readings were Ն70% of the expected number of readings (nϭ92), and at least 1 valid reading per hour for at least 21 of the 24 hours was considered. In the group as a whole (see below), valid BP readings were 85.7% of the expected number of readings at baseline and 83.5%, 86.0%, 85.4%, and 85.7% from the first to the fourth year of the treatment period, respectively. In each patient, the mean of the 24-hour SBP and DBP values was considered the 24-hour representative yearly value.
Carotid IMT Measurements
Duplicate carotid scans (B mode) were obtained by certified sonographers at baseline and at yearly intervals during treatment. Scans were obtained 4 years after randomization in patients who withdrew prematurely. The same type of instrument (Biosound 2000 II SA) was used in all centers throughout the study. All scans were read centrally by a limited number of readers blinded to treatment and, after the end of the study, the scan sequences. 10, 15 The maximum IMT value was measured at several levels of the 4 far walls of the common carotids and carotid bifurcations, and the mean (CBMmax) was taken as the representative baseline or yearly on-treatment value. Quality assurance was accomplished as reported in detail previously. 16 
Cardiovascular Events
The incidence of the following events was monitored throughout the study by an Event Monitoring Committee blinded to treatment allocation according to predetermined criteria 10 : fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, major cardiovascular events (including fatal and nonfatal myocardial infarction, stroke, and cardiovascular death), death resulting from any cause, minor cardiovascular events (hospitalized heart failure, angina, atrial fibrillation, and claudication), and all major and minor cardiovascular events. Because they were not the primary end point, nonfatal cardiovascular events did not lead to interruption of treatment; therefore, on-treatment BP measurements continued until the end of the trial.
Data Analysis
Long-term intraindividual, visit-to-visit BP variability was analyzed separately for the 3 treatment groups and in the group as a whole. Pooling of the data from the 3 treatment groups was justified by the evidence that the on-treatment CVs or SDs of SBP and DBP (see below) were substantially similar between the atenolol-and lacidipine-treated patients. 17 In each patient, visit-to-visit (long-term) SBP and DBP variabilities were calculated as the SD of the mean of the BP values measured at each visit during the treatment period, separately for the clinic and the 24-hour mean BP values. For clinic BP, only BP values from the 6-month visit onward were considered so that the BP changes occurring during the drug titration phase were not included in the calculation. Except for data included in the multivariable analysis of the incidence of cardiovascular events (see below), only patients in whom 7 or more clinic or 3 or more 24-hour mean BP values were available were analyzed to avoid calculating SDs from too few measurements. In each patient, the SD was divided by the corresponding on-treatment BP mean to express visit-to-visit variability also as a CV, ie, a normalized value. Individual values were averaged to obtain mean values for each group considered (see below).
Influence of Visit-to-Visit BP Variability on Carotid IMT
Because a measure of visit-to-visit BP variability can be obtained only at the end of a trial, data could not be analyzed by timedependent proportional hazard models. Therefore, the relationship of long-term BP variability with carotid CBMmax was examined by 2 different approaches: a continuous model and a categorical approach in which SBP and DBP values were subdivided into 4 consecutive quartiles.
Continuous Model Approach
To identify the factors independently associated with end-oftreatment carotid CBMmax, a linear regression model was used that allowed continuously distributed variables such as carotid IMT and BP (clinic and 24 hour) to be related in a continuous fashion. The variables (age, sex, history of diabetes mellitus, serum total and high-density lipoprotein cholesterol, smoking, baseline carotid CBMmax, treatment type [atenolol or lacidipine], baseline clinic and 24-hour SBP and DBP mean values, and on-treatment clinic and 24-hour SBP and DBP means, SDs, and alternatively CVs) were entered into the model by stepwise selection. A semipartial correlation (Rp 2 ) was used to determine the level of statistical significance.
Categorical Approach
Visit-to-visit CVs or SDs of clinic SBP or DBP were divided into quartiles, and the average CBMmax at the end of the 4-year treatment was calculated for each quartile. The statistical significance of the relation of CBMmax to CV or SD was assessed before and after adjustment for the confounding factors also used in the continuous model. When the SD was used as variability index, data were adjusted for on-treatment SBP or DBP mean values, whereas this was not done when CV was used to avoid adjusting twice for the same factor. The same approach was used for relating carotid CBMmax at the end of the 4-year treatment to quartiles of ontreatment clinic SBP or DBP means, except that in this case data were adjusted for on-treatment clinic SBP or DBP CV (or SD). The relationship of 24-hour SBP or DBP means or CVs to carotid CBMmax was also analyzed in the same fashion. Because end-oftreatment carotid IMT and clinic and 24-hour BP means and between-visit variabilities displayed a normal distribution, no correction was made for outliers. The statistical significance of the between-group differences was assessed by the t test for unpaired observations. Between-quartile trends for demographic and clinical variables were tested by the use of integer values (1, 2, 3, and 4) in a linear regression model. Throughout the text, group values are expressed as meanϮSD. All P values were 2 sided, and a value of PϽ0.05 was considered statistically significant. The statistical analysis was carried out by SAS version 9.1 (SAS Institute, Cary, NC).
Influence of Visit-to-Visit BP Variability on Cardiovascular Events
A logistic multivariable model was used to identify the variables independently associated with cardiovascular events, again entering the variables into the model by stepwise selection and alternatively using clinic and 24-hour BP values. Only BP values before the event were used to calculate visit-to-visit BP variability. The 2 score was used to determine the level of significance.
Results
Relation of CBMmax to On-Treatment Clinic and Ambulatory BP Means and Variabilities
A total of 1521 and 1264 patients met the criteria for relating carotid IMT at the end of the 4-year treatment period to intraindividual visit-to-visit clinic and ambulatory BP variability, respectively. In the clinic BP sample mean age was 55.8Ϯ7.4 years, male prevalence was 55.8%, and body mass index was 27 ) shows the results of the stepwise multivariable analysis that considered the end-of-treatment CBMmax as the continuous dependent variable and a number of baseline and on-treatment factors as the independent ones. In the model including clinic BP, the factors independently favoring a greater end-of-treatment carotid CBMmax were the baseline CBMmax value, followed (with much less impact) by age and on-treatment clinic SBP mean, whereas baseline clinic DBP, serum high-density lipoprotein cholesterol, and the on-treatment clinic SBP CV had an opposite effect. The results were similar when SD replaced CV as a measure of visit-to-visit BP variability in the model, except for the disappearance of visit-to-visit SBP variability as a predictor. Similar results were obtained when the model used the 24-hour rather than the clinic BP (Table 1 , bottom), except that the independent predictors did not include any baseline BP and included serum total cholesterol. In addition, in this model, neither SBP CV or SBP SD values contributed positively to a greater end-of-treatment carotid CBMmax.
In addition to the continuous analysis, a categorical analysis was done by dividing patients by quartiles of SBP SD or CV. From the lowest to the highest quartile of on-treatment clinic SBP CV there was a slight increase in age, baseline body mass index, and clinic and ambulatory DBP values, together with a reduction in prevalence of the male sex ( Table  2 ). The quartiles of on-treatment clinic SBP mean were accompanied by similar differences in patient characteristics (Table I in the online-only Data Supplement). This was also the case for the quartiles of SBP SD and the corresponding DBP quartiles (data not shown).
As shown in Figure 1 , top left, the end-of-treatment carotid CBMmax increased progressively from the quartile with the lowest to the quartile with the highest on-treatment clinic SBP mean, with a P value for trend that remained significant after adjustment for confounders (see Methods). Carotid CBMmax was similar in the different quartiles of ontreatment clinic SBP CV or SD (Figure 1 , middle and bottom left), with an adjusted P value that for SBP CV indicated a very small trend in the reverse direction, ie, a slightly lower CBMmax at the highest CV. There was no significant CBMmax difference between quartiles of on-treatment clinic DBP mean, CV, or SD (Figure 1, right) . Similar results were obtained when SBP data were calculated separately for the atenolol-and lacidipine-treated groups, although the smaller quartile sizes did not allow the trend to an increase in carotid IMT with an increase in on-treatment SBP mean to be significant (Table II in Similar results were found when end-of-treatment CBMmax was related to quartiles of 24-hour BP variabilities. By and large, patient characteristics differed between the quartiles of on-treatment 24-hour SBP mean, as reported for the corresponding quartiles of clinic SBP (Table III in the online-only Data Supplement), whereas the quartiles of 24-hour SBP CV were not accompanied by significant differences in patient characteristics (Table IV in the online-only Data Supplement). This was the case also for the 24-hour DBP quartiles (data not shown). As illustrated in Figure 2 , top left, the end-of-treatment carotid CBMmax increased progressively and significantly from the quartile with the lowest to the quartile with the highest on-treatment 24-hour SBP mean. Carotid CBMmax showed no significant difference between quartiles of on-treatment 24-hour SBP CV or SD (Figure 2 , middle and bottom left) and was similar between quartiles of on-treatment 24-hour DBP mean, CV, or SD (Figure 2, right) . Similar results were obtained when data were calculated separately for atenolol and lacidipine, al- though with a trend between an increase in 24-hour BP mean and an increase in carotid IMT that was significant in the lacidipine group only (Table II in 
Relation of Cardiovascular Events With On-Treatment BP Means and Variabilities
As shown in Table 3 , when cardiovascular events were considered the dependent variable, either on-treatment clinic or 24-hour SBP mean independently contributed to the risk of a cardiovascular event, in addition to sex and serum total cholesterol. The results were identical if SD was substituted for CV as a measure of visit-to-visit BP variability.
Furthermore, in the group of patients in whom there was a cardiovascular event, on-treatment clinic and 24-hour mean SBP values (145.6Ϯ13.1 and 136.9Ϯ13.5 mm Hg, respectively) were significantly greater compared with those in the group in which no event occurred (141.8Ϯ11.1 and 131.6Ϯ11.9 mm Hg; Pϭ0.006 and 0.002), whereas the corresponding on-treatment SBP CV did not exhibit any significant between-group differences. Similarly, as shown in Figure 3 , in the group of patients with a clinic or 24-hour SBP mean above the median value for the entire ELSA cohort, the rate of cardiovascular events was significantly greater than in the group with a clinic or 24-hour SBP mean below the median value. In contrast, the incidence of cardiovascular events did not show a statistically significant difference between groups with an on-treatment SBP variability (SD or CV, clinic or 24 hours) above or below the median value. This was also the case for clinic or 24-hour DBP mean, SD, or CV.
In patients (nϭ37) experiencing a cardiovascular event in whom 4 or 5 clinic BP values were available both before and after the event, clinic SBP mean (141.0 versus 145.7 mm Hg; Pϭ0.02) was significantly lower after the event occurrence, whereas the clinic SBP SD (8.6 versus 9.9; Pϭ0.43) and CV (5.9 versus 7.1; Pϭ0.29) were similar before and after the event occurrence.
Discussion
In the mildly to moderately hypertensive patients of the ELSA trial, the carotid IMT (CBMmax) at the end of the 4-year treatment period showed a progressively greater value from the quartile with the lowest to the quartile with the highest on-treatment clinic or 24-hour SBP mean, but it did not show any noticeable or consistent variation from the quartile with the lowest to the quartile with the highest intraindividual on-treatment visit-to-visit SBP SD or CV. Furthermore, when considered as a dependent continuous variable, the end-of-treatment IMT showed an independent relationship with a number of factors that included the previous on-treatment clinic or 24-hour SBP mean but not the previous on-treatment intraindividual visit-to-visit SBP vari- *Factors included as potential independent variables are those mentioned in Table 3 . The factors independently predicting cardiovascular events remained the same by inclusion of coefficient of variation or SD of SBP and diastolic BP mean as a measure of visit-to-visit BP variability, neither of which was an independent predictor. abilities. Finally, clinic and 24-hour on-treatment SBP means were significantly higher in patients experiencing a cardiovascular event, whereas intraindividual on-treatment clinic or 24-hour SBP variability did not show any significant difference between patients who did and did not have an event. In addition, the occurrence of events was independently predicted by on-treatment clinic or 24-hour mean SBP values but again not by intraindividual on-treatment SBP SD or CV (ie, absolute or normalized variabilities).
This leads to the conclusion that in the ELSA patients intraindividual SBP variations throughout the treatment period did not play any measurable independent prognostic role over and above that played by the average on-treatment SBP. This was consistently the case when the prognostic role was directly assessed by the incidence of clinically manifest events and when it was indirectly inferred from carotid IMT based on the evidence that carotid IMT predicts cardiovascular risk. 11, 12 At variance from our observations, Rothwell and coworkers 1 found that in patients in the United Kingdom Transient Ischaemic Attack Aspirin Trial (UK-TIA) trial, all with a history of a cerebrovascular event, intraindividual visit-tovisit BP variability was positively related to the risk of stroke recurrence. Those investigators also found that in the hypertensive patients of ASCOT 6 and MRC-elderly, 7 the risk of stroke and coronary fatal or nonfatal events became progressively greater as intraindividual on-treatment visit-to-visit BP variability increased. 1 We have no direct explanation for the discrepancy between the above-mentioned results and those reported here. However, in UK-TIA, ASCOT, and MRCelderly, the patients were older than the ELSA patients and previous cardiovascular events, diabetes mellitus, and other additional cardiovascular risk factors were much more common than in the ELSA patients, in whom, despite the carotid artery wall alterations, the 10-year risk of cardiovascular morbidity and mortality was only 8.4%, 12 ie, less than half of the risk in ASCOT and one third that of MRC-elderly. We can thus speculate that the clinical importance of visit-tovisit BP variability depends on the level of total cardiovascular risk. That is, intraindividual BP variability during treatment may play a prognostic role when vascular damage is high, whereas it does not contribute substantially to the progression of vascular damage when cardiovascular risk is relatively low. This may find support in 2 further pieces of evidence. First, in the hypertensive patients of the International Verapamil SR-Trandolapril Study (INVEST), all of whom had a history of coronary disease and thus were all at high cardiovascular risk, cardiovascular outcome was steeply related to the percentage of visits in which clinic BP was controlled to Ͻ140/ 90 mm Hg, independently of the achieved clinic mean BP throughout the treatment period. 18 Second, in the high-cardiovascular-risk patients of the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET), the occurrence of a cardiovascular event, particularly stroke, was independently related to the presence or absence of a reduction in clinic BP to Ͻ140/90 mm Hg in the immediately preceding visit. 19 Several other results of our study deserve mention. Both clinic and 24-hour on-treatment mean SBP values were found to be independently and positively associated with carotid IMT and the incidence of cardiovascular events, whereas, with 1 exception, this was not the case for baseline clinic or 24-hour SBP. In a previous analysis of baseline ELSA data, we had shown that baseline clinic and 24-hour SBP values and a 24-hour variability index (short-term variability) had a low but significant correlation with baseline IMT. 20 Comparison of these previous findings with those of the present study suggests that a few-year period of BP control by treatment may overcome the prognostic impact of the previous elevated BP values. For ambulatory BP, this represents new evidence because, with few exceptions, 21 previous demonstrations of its prognostic importance have been derived mainly from population-based studies or cohorts rather than treated hypertensive patients. [22] [23] [24] In addition, in the ELSA patients, clinic or 24-hour mean SBP showed prognostic importance, whereas mean DBP did not. This finding offers further support to the already large body of evidence showing that at least from middle age on, SBP is a more important prognostic factor than DBP. 25, 26 Finally, taking advantage of the fact that in ELSA BP measurements and randomized treatments continued after a nonfatal cardiovascular event (because cardiovascular events were not the primary end point), our results provide the first available evidence that intraindividual visit-to-visit BP variability does not seem to be substantially modified by an event occurrence. This may justify inclusion of preand post-nonfatal event BP variations in the calculations of intraindividual visit-to-visit variabilities in future studies.
Our study has limitations and some specific strengths. An important limitation is that, as in the previous studies of Rothwell and coworkers, 1 the results are based on a post hoc analysis of trial data, which means that the conclusion on the marginal role of visit-to-visit BP variability on progression of organ damage or incidence of cardiovascular events is based on comparisons between nonrandomized groups. Therefore, the results may depend on variables other than that under study, a possibility that cannot be entirely eliminated by adjusting for a large number of potential confounders, as Rothwell et al have done in their analyses and we have done in our study. Another limitation is that because the patients involved in the ELSA trial were at low to moderate cardiovascular risk, the number of cardiovascular events that occurred throughout the study (nϭ115) was small, and thus there was a limited ability to discriminate possible differences in hard end points between groups with different visit-to-visit BP variabilities. A third limitation is that only the prognostic significance of the absolute value of carotid artery wall thickness is well established both in the general population and in hypertensive individuals, 11, 12 whereas the prognostic value of changes in carotid IMT induced by treatment remains an unsettled question, 27, 28 possibly because treatment-induced IMT changes are too small to modify the prognostic significance of absolute IMT values, which vary over a much wider range. 12 It should be emphasized, however, that in our study we have not used treatment-induced
